{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:23:58Z","timestamp":1760145838795,"version":"build-2065373602"},"reference-count":66,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Following the advent of direct-acting antivirals (DAAs), the treatment of hepatitis C virus (HCV) infection is now rarely challenging. However, data are still limited concerning DAA use in patients affected by glucose-6-phosphate dehydrogenase deficiency (G6PDd). Based on these considerations, the goal of this study was to evaluate the effectiveness and safety of DAAs in this subpopulation. A retrospective multicenter observational study (2015\u20132023) was conducted on all 2754 consecutive HCV-positive patients treated with first- and second-generation all-oral DAAs, and with a G6PDd diagnosis confirmed by quantitative testing (n = 38). At the treating clinician\u2019s discretion, an enhanced clinical and laboratory follow-up was performed, generally on a monthly basis both during treatment and up to six months after the end of it. Concerning hematochemical parameters, no significant differences were found between any considered time point. In all cases, no treatment-related adverse events were reported, and virologic response rates were as expected without G6PDd. In conclusion, in a large experience which, to the best of our knowledge, is unprecedented in the literature, the treatment of HCV hepatitis with nearly all available DAAs in patients with G6PDd as a comorbidity\u2014a common occurrence in countries such as Italy\u2014proved to be highly effective and safe.<\/jats:p>","DOI":"10.3390\/genes15091116","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T01:48:49Z","timestamp":1724636929000},"page":"1116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3338-5416","authenticated-orcid":false,"given":"Carlo","family":"Smirne","sequence":"first","affiliation":[{"name":"Internal Medicine Unit, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"},{"name":"Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Crobu","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Virology, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"},{"name":"Clinical Biochemistry Laboratory, City of Health and Science University Hospital, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Gerevini","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-2624","authenticated-orcid":false,"given":"Alessandro","family":"Berton","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, City of Health and Science University Hospital, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Rapetti","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4373-1212","authenticated-orcid":false,"given":"Barbara","family":"Pasini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10126 Turin, Italy"},{"name":"Division of Medical Genetics, City of Health and Science University Hospital, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ravanini","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Virology, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-0155","authenticated-orcid":false,"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Maggiore della Carit\u00e0 Hospital, 28100 Novara, Italy"},{"name":"Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"188K","DOI":"10.2471\/BLT.19.231522","article-title":"Effectiveness of Generic Direct-Acting Agents for the Treatment of Hepatitis C: Systematic Review and Meta-Analysis","volume":"98","author":"Perazzo","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jceh.2018.07.004","article-title":"New Direct-Acting Antivirals for the Treatment of Patients with Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials","volume":"9","author":"Pecoraro","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/jvh.13679","article-title":"Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (\u226565 Years Old): A Systematic Review and Meta-Analysis","volume":"29","author":"Lee","year":"2022","journal-title":"J. Viral Hepat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14656566.2024.2358139","article-title":"Revolutionizing Hepatitis C Treatment: Next-Gen Direct-Acting Antivirals","volume":"25","author":"Dobrowolska","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2019000944","article-title":"Glucose-6-Phosphate Dehydrogenase Deficiency","volume":"136","author":"Luzzatto","year":"2021","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bcmd.2008.12.005","article-title":"The Global Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency: A Systematic Review and Meta-Analysis","volume":"42","author":"Nkhoma","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Alangari, A.S., El-Metwally, A.A., Alanazi, A., Al Khateeb, B.F., Al Kadri, H.M., Alshdoukhi, I.F., Aldubikhi, A.I., Alruwaili, M., and Alshahrani, A. (2023). Epidemiology of Glucose-6-Phosphate Dehydrogenase Deficiency in Arab Countries: Insights from a Systematic Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206648"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e18437","DOI":"10.1016\/j.heliyon.2023.e18437","article-title":"Glucose-6-Phosphate Dehydrogenase Deficiency among Neonates with Jaundice in Africa; Systematic Review and Meta-Analysis","volume":"9","author":"Kassahun","year":"2023","journal-title":"Heliyon"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1708111","article-title":"Favism and Glucose-6-Phosphate Dehydrogenase Deficiency","volume":"378","author":"Luzzatto","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.hoc.2015.11.006","article-title":"Glucose-6-Phosphate Dehydrogenase Deficiency","volume":"30","author":"Luzzatto","year":"2016","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/hep.20208","article-title":"Low Membrane Protein Sulfhydrils but Not G6PD Deficiency Predict Ribavirin-Induced Hemolysis in Hepatitis, C","volume":"39","author":"Grattagliano","year":"2004","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2005-11-4508","article-title":"Treatment of Chronic Hepatitis C in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency: Is Ribavirin Harmful?","volume":"107","author":"Balestrieri","year":"2006","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhep.2006.10.003","article-title":"Tolerability of Peg Interferon-A2b and Ribavirin Therapy in Patients with Chronic Hepatitis C and Glucose-6-Phosphate Dehydrogenase Deficiency","volume":"46","author":"Demelia","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Shiha, G., Soliman, R., ElBasiony, M., and Mikhail, N.N.H. (2018, January 14-18). Ledipasvir 90 Mg\/Sofosbuvir 400 Mg for 12 Weeks for the Treatment of CHC Genotype 4 Adolescents. Proceedings of the 27th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), New Delhi, India.","DOI":"10.1016\/S0168-8278(18)30748-7"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2141.1979.tb03774.x","article-title":"International Committee for Standardization in Haematology: Recommended Screening Test for Glucose--6--Phosphate Dehydrogenase (G--6--PD) Deficiency","volume":"43","author":"Blume","year":"1979","journal-title":"Br. J. Haematol."},{"key":"ref_16","first-page":"191","article-title":"Standardization Problems Relevant to Quantitative Laboratory Methods for Glucose 6-Phosphate Dehydrogenase Deficiency Detection","volume":"15","author":"Paleari","year":"1990","journal-title":"G. Ital. Chim. Clin."},{"key":"ref_17","first-page":"397","article-title":"Preliminary Experience with the Differential PH Technique for Glucose-6-Phosphate Dehydrogenase (G6PD) Measurement in Whole Blood: Application to an Area with High Prevalence of Thalassaemia and G6PD Deficiency","volume":"75","author":"Mosca","year":"1990","journal-title":"Haematologica"},{"key":"ref_18","first-page":"1","article-title":"Standardization of Procedures for the Study of Glucose-6-Phosphate Dehydrogenase. Report of a WHO Scientific Group","volume":"366","author":"Betke","year":"1967","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"ref_19","unstructured":"Maffi, D., Caforio, M.P., Pasquino, M.T., and Caprari, P. (2009). Glucose-6-Phosphate Dehydrogenase Deficiency and Drugs (Report 09\/47). Italian National Institute of Health Reports, Italian National Institute of Health."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjh.18943","article-title":"Genetic Variants Causing G6PD Deficiency: Clinical and Biochemical Data Support New WHO Classification","volume":"202","author":"Nannelli","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3109\/10715762.2014.913788","article-title":"Glucose-6-Phosphate Dehydrogenase-beyond the Realm of Red Cell Biology","volume":"48","author":"Ho","year":"2014","journal-title":"Free Radic. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","article-title":"Glucose-6-Phosphate Dehydrogenase Deficiency","volume":"371","author":"Cappellini","year":"2008","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modelling Study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mcg.0000145494.76305.11","article-title":"Hematologic Side Effects of Interferon and Ribavirin Therapy","volume":"39","author":"Kowdley","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-199906000-00001","article-title":"Hemolytic Anemia and the Treatment of Chronic Hepatitis C: Editorial","volume":"28","author":"Saab","year":"1999","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic Anemia Induced by Ribavirin Therapy in Patients with Chronic Hepatitis C Virus Infection: Role of Membrane Oxidative Damage","volume":"31","author":"Fattovich","year":"2000","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in Haemoglobin during Interferon alpha -2b plus Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J. Viral Hepat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00004836-199906000-00017","article-title":"Hemolytic Anemia Secondary to alpha-Interferon Treatment in a Patient with Chronic C Hepatitis","volume":"28","year":"1999","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-2036.2010.04269.x","article-title":"Review Article: Optimizing SVR and Management of the Haematological Side Effects of Peginterferon\/Ribavirin Antiviral Therapy for HCV\u2014The Role of Epoetin, G-CSF and Novel Agents","volume":"31","author":"Norris","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3949\/ccjm.71.Suppl_3.S17","article-title":"Managing the Hematologic Side Effects of Antiviral Therapy for Chronic Hepatitis C: Anemia, Neutropenia, and Thrombocytopenia","volume":"71","author":"Ong","year":"2004","journal-title":"Cleve Clin. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00535-004-1391-0","article-title":"Ribavirin-Induced Hemolytic Anemia in Chronic Hepatitis C Patients","volume":"39","author":"Itoh","year":"2004","journal-title":"J. Gastroenterol."},{"key":"ref_32","unstructured":"Bini, E.J., Anand, B.S., Aytaman, A., Samanta, A., Cordoba-Rellosa, I., Nemchausky, B., Trevino, H.H., Mah\u2019moud, M.A., Weston, A.P., and Pimstone, N.R. (2005, January 11-15). Glucose-6-Phosphate Dehydrogenase Deficiency Is Associated with Severe Anemia during Interferon and Ribavirin Therapy. Proceedings of the 56th Annual Meeting of the American Association for The Study of Liver Diseases (AASLD), San Francisco, CA, USA."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1749-6632.1974.tb20594.x","article-title":"The Interaction between beta-Thalassemia, G-6-PD Deficiency, and Favism","volume":"232","author":"Carcassi","year":"1974","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2893.2000.00199.x","article-title":"Impact of Hepatitis C Virus Infection on Healthy Subjects on an Italian Island","volume":"7","author":"Coppola","year":"2000","journal-title":"J. Viral Hepat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for Untreated Chronic HCV Genotype 1 Infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for Retreatment of HCV Infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s40265-013-0153-9","article-title":"Simeprevir: First Global Approval","volume":"73","author":"Vaidya","year":"2013","journal-title":"Drugs"},{"key":"ref_40","first-page":"345","article-title":"Sofosbuvir: A New Oral Once-Daily Agent for the Treatment of Hepatitis C Virus Infection","volume":"39","author":"Cha","year":"2014","journal-title":"Pharm. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r\u2013Ombitasvir and Dasabuvir with or without Ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","article-title":"Daclatasvir plus Peginterferon Alfa and Ribavirin for Treatment-Naive Chronic Hepatitis C Genotype 1 or 4 Infection: A Randomised Study","volume":"64","author":"Hirschfield","year":"2015","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"355.e1","DOI":"10.1053\/j.gastro.2014.10.007","article-title":"Daclatasvir plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection","volume":"148","author":"Dore","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct Acting Anti-Hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Int. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series\u2606","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment Failure with DAA Therapy: Importance of Resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nefro.2019.03.013","article-title":"Efficacy and Safety of Direct-Acting Antiviral Agents for HCV in Mild-to-Moderate Chronic Kidney Disease","volume":"40","author":"Ridruejo","year":"2020","journal-title":"Nefrolog\u00eda"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/jgh.15051","article-title":"Efficacy and Safety of Direct Acting Antiviral Regimens for Hepatitis C Virus and Human Immunodeficiency Virus Co-Infection: Systematic Review and Network Meta-Analysis","volume":"35","author":"Zheng","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gualerzi, A., Bellan, M., Smirne, C., Tran Minh, M., Rigamonti, C., Burlone, M.E., Bonometti, R., Bianco, S., Re, A., and Favretto, S. (2018). Improvement of Insulin Sensitivity in Diabetic and Non Diabetic Patients with Chronic Hepatitis C Treated with Direct Antiviral Agents. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0209216"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e00811","DOI":"10.1002\/prp2.811","article-title":"Sofosbuvir-Based Therapies in Genotype 2 Hepatitis C Virus Cirrhosis: A Real-Life Experience with Focus on Ribavirin Dose","volume":"9","author":"Smirne","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5152\/eurasianjmed.2022.20421","article-title":"Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients","volume":"54","author":"Smirne","year":"2022","journal-title":"Eurasian J. Med."},{"key":"ref_56","first-page":"3","article-title":"Response Rates to Direct Antiviral Agents among Hepatitis C Virus Infected Patients Who Develop Hepatocellular Carcinoma Following Direct Antiviral Agents Treatment","volume":"6","author":"Burlone","year":"2020","journal-title":"Hepatoma Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10020-023-00666-x","article-title":"The Pre-Conception Maternal Exposure to Sofosbuvir Affects the Mitochondrial Biogenesis in Prenatal Fetal Tissues: Experimental Study on Rats","volume":"29","author":"Mahmoud","year":"2023","journal-title":"Mol. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Ali, R.A., Awadalla, E.A., Amin, Y.A., Fouad, S.S., Ahmed, M.A.E.B., Hassan, M.H., Abdel-Kahaar, E., and Abdel-Aziz, R.H. (2024). The Deleterious Effects of Sofosbuvir and Ribavirin (Antiviral Drugs against Hepatitis C Virus) on Different Body Systems in Male Albino Rats Regarding Reproductive, Hematological, Biochemical, Hepatic, and Renal Profiles and Histopathological Changes. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55950-5"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.12816\/0043187","article-title":"Effects of Sofosbuvir and Ribavirin on Some Haematological and Biochemical Parameters in Normal Rats","volume":"68","author":"Elarabany","year":"2017","journal-title":"Egypt. J. Zool."},{"key":"ref_60","first-page":"MR000021","article-title":"Incentives and Disincentives to Participation by Clinicians in Randomised Controlled Trials","volume":"2007","author":"Rendell","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_61","first-page":"MR000030","article-title":"Consolidated Standards of Reporting Trials (CONSORT) and the Completeness of Reporting of Randomised Controlled Trials (RCTs) Published in Medical Journals","volume":"11","author":"Turner","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_62","first-page":"MR000024","article-title":"New Treatments Compared to Established Treatments in Randomized Trials","volume":"10","author":"Djulbegovic","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_63","first-page":"MR000039","article-title":"Eliciting Adverse Effects Data from Participants in Clinical Trials","volume":"1","author":"Allen","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref_64","first-page":"MR000038","article-title":"Interventions to Prevent Misconduct and Promote Integrity in Research and Publication","volume":"4","author":"Marusic","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_65","first-page":"MR000051","article-title":"Monitoring Strategies for Clinical Intervention Studies","volume":"12","author":"Klatte","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_66","first-page":"MR000013","article-title":"Strategies to Improve Recruitment to Randomised Trials","volume":"2","author":"Treweek","year":"2018","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/9\/1116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:42:40Z","timestamp":1760110960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/9\/1116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["genes15091116"],"URL":"https:\/\/doi.org\/10.3390\/genes15091116","relation":{},"ISSN":["2073-4425"],"issn-type":[{"type":"electronic","value":"2073-4425"}],"subject":[],"published":{"date-parts":[[2024,8,24]]}}}